Clinical Trial Update: Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Acute Treatment of Temporomandibular Disorders [Phase 3]

View source ↗

Summary

Pfizer-sponsored Phase 3 trial evaluating BHV-3000 (rimegepant) orally disintegrating tablet for acute treatment of temporomandibular disorders was terminated, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Temporomandibular Disorders

Drugs mentioned

• BHV-3000 (Rimegepant) Oral Disintegrating Tablet (rimegepant)

Snippet

Sponsor: Pfizer | Conditions: Temporomandibular Disorders (TMD) | Phase 3 | Status: TERMINATED | Results posted: 2024-05-16